ArticleOncogene2000
The amino-terminus and membrane-spanning domains of LMP-1 inhibit cell proliferation.
Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 67 citations in OpenAlex.
- Decoding Critical Targets and Signaling Pathways in EBV-Mediated Diseases Using Large Language Models.Viruses · 2024Article
- Simiao Qingwen Baidu decoction inhibits Epstein-Barr virus-induced B lymphoproliferative disease and lytic viral replication.Pharmaceutical biology · 2021Article
- c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.Journal of virology · 2018Article
- Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.Oncotarget · 2017Article
- Article
- How human tumor viruses make use of autophagy.Cells · 2012Article
- The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus can simultaneously induce and inhibit apoptosis in B cells.Journal of virology · 2012Article
- Nasopharyngeal carcinoma signaling pathway: an update on molecular biomarkers.International journal of cell biology · 2012Article
- Transmembrane peptides used to investigate the homo-oligomeric interface and binding hotspot of latent membrane protein 1.Biopolymers · 2011Article
- NF-kappaB activation stimulates transcription and replication of retrovirus XMRV in human B-lineage and prostate carcinoma cells.Journal of virology · 2011Article
- Epstein-Barr virus BART9 miRNA modulates LMP1 levels and affects growth rate of nasal NK T cell lymphomas.PloS one · 2011Article
- The p38 signaling pathway upregulates expression of the Epstein-Barr virus LMP1 oncogene.Journal of virology · 2010Article
- Augmented latent membrane protein 1 expression from Epstein-Barr virus episomes with minimal terminal repeats.Journal of virology · 2010Article
- Synergism of BARF1 with Ras induces malignant transformation in primary primate epithelial cells and human nasopharyngeal epithelial cells.Neoplasia (New York, N.Y.) · 2009Article
- Inhibition of p38 MAP kinase pathway induces apoptosis and prevents Epstein Barr virus reactivation in Raji cells exposed to lytic cycle inducing compounds.Molecular cancer · 2009Article
- Nuclear factor-kappaB binds to the Epstein-Barr Virus LMP1 promoter and upregulates its expression.Journal of virology · 2009Article
- The unfolded protein response and autophagy: herpesviruses rule!Journal of virology · 2009Review
- Noncoding RNAs produced by oncogenic human herpesviruses.Journal of cellular physiology · 2008Review
- Molecular basis of cytotoxicity of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) in EBV latency III B cells: LMP1 induces type II ligand-independent autoactivation of CD95/Fas with caspase 8-mediated apoptosis.Journal of virology · 2008Article
- The latent membrane protein 1 oncogene modifies B-cell physiology by regulating autophagy.Oncogene · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The LMP-1 oncoprotein of EBV is required to maintain proliferation of infected B-cells and shares several features with CD40, TNF-R1, and related receptors. Members of this family can bind TRAF and TRADD molecules and activate NF-kappaB and AP-1, as can LMP-1. While CD40 and TNF-R1 are dependent on binding their ligands for their signaling, LMP-1 apparently is not. We have found that LMP-1 can act as a governor of cell proliferation and thereby limit its own activities. Its inhibition of proliferation is not mediated by apoptosis but results in cytostasis in four cell lines tested. The structural moiety of LMP-1 that distinguishes it from CD40 and TNF-R1, its amino-terminus and multiple membrane spanning segments, alone can mediate its cytostatic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.